Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC Prefilled Syringe in Thyroid Eye Disease
2023-509198-22-00Phase 3Completed
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Efgartigimod PH20 SC (Vyvgart) with Placebo (2 arms). Primary endpoint: Proptosis responders at DBTP week 24. Started Oct 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-509198-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509198-22-00.